InterCure reports preliminary FY25 revenue NIS 265M

Adjusted EBITDA is expected to be positive in both the first and second halves of 2025, marking the Company’s twelfth consecutive half-year of positive Adjusted EBITDA. Cash on hand of NIS 43M as of December 31, 2025. Alexander Rabinovich, CEO noted: “2025 marked a year of disciplined execution and renewed growth for InterCure (INCR). We delivered meaningful acceleration in the second half of the year with nearly 20% revenue growth and achieved our twelfth consecutive half-year of positive Adjusted EBITDA. The anticipated commencement of operations under the Botanico transaction and our strategic collaboration with Cannasoul are expected to further strengthen our pharmaceutical platform and global positioning. This marks another key milestone with our first significant revenues in the German market, as we expect continued execution of our global expansion strategy in Germany and additional markets throughout 2026. As regulatory frameworks continue to evolve, particularly in the United States and Europe, we believe InterCure is strategically positioned to leverage its vertically integrated model, scientific leadership, and international partnerships to drive long-term value for patients and shareholders.”